A real-world analysis using more than 10,000 patients in the IRIS Registry found that routine injections of avacincaptad pegol for geographic atrophy occurred at an average interval of seven weeks, with a low rate of acute adverse events. The findings translate pivotal dosing concepts into day-to-day practice patterns across care settings. The data will likely be used by retina clinicians and payers to benchmark adherence to dosing schedules and inform counseling around monitoring and expected clinic frequency.
Get the Daily Brief